BioSpace News Archive

Pharm Country

Henry Schein to Participate in UBS Global Healthcare Investor Conference

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that the Company will present at the UBS Global Healthcare Conference on May 24, 2022, at 2:00 p.m. Eastern time.

May 5, 2022
·
2 min read
Drug Development

SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

SQZ Biotechnologies announced that the company will present data from the first non-clinical studies of its point-of-care manufacturing system at the 2022 American Society for Gene and Cell Therapy Annual Meeting on May 18.

May 5, 2022
·
8 min read
Philogen to Present at UBS Global Healthcare Conference

Philogen S.p.A. today announces that it will present at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace.

May 5, 2022
·
2 min read
Policy

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher Holdings Ltd. is pleased to announce that the United States Patent and Trademark Office granted US Patent No: 11,286,230, titled “Ketamine Flow Synthesis”, which refers to a continuous-flow process technology for the preparation of ketamine and ketamine analogs.

May 5, 2022
·
5 min read
Biotech Bay

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies.

May 5, 2022
·
5 min read
Business

AlloVir Reports First Quarter 2022 Financial Results

AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022.

May 5, 2022
·
10 min read
BioCapital

FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

May 5, 2022
·
12 min read
Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.

May 5, 2022
·
27 min read
Deals

Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments

Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept.

May 5, 2022
·
17 min read
Business

Acerus To Report Q1-2022 Financial Results And Host Investor Call

Acerus Pharmaceuticals Corporation will announce its first quarter 2022 financial and operating results on Tuesday, May 10, 2022 before the market opens.

May 5, 2022
·
1 min read